Abstract:Pulmonary arterial hypertension (PAH) is a malignant pulmonary vascular syndrome characterized by a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, which eventually leads to right heart failure and even death. Although the exact mechanism of PAH is not fully understood, pulmonary vasoconstriction, vascular remodeling, immune and inflammatory responses, and thrombosis are thought to be involved in the development and progression of PAH. In the era of non-targeted agents, PAH had a very dismal prognosis with a median survival time of only 2.8 years. With the deep understanding of the pathophysiological mechanism of PAH as well as advances in drug research, PAH-specific therapeutic drugs have developed rapidly in the past 30 years, but they primarily focus on the three classical signaling pathways, namely the endothelin pathway, nitric oxide pathway, and prostacyclin pathway. These drugs dramatically improved pulmonary hemodynamics, cardiac function, exercise tolerance, quality of life, and prognosis in PAH patients, but could only reduce pulmonary arterial pressure and right ventricular afterload to a limited extent. Current targeted agents delay the progression of PAH but cannot fundamentally reverse pulmonary vascular remodeling. Through unremitting efforts, new therapeutic drugs such as sotatercept have emerged, injecting new vitality into this field. This review comprehensively summarizes the general treatments for PAH, including inotropes and vasopressors, diuretics, anticoagulants, general vasodilators, and anemia management. Additionally, this review elaborates the pharmacological properties and recent research progress of twelve specific drugs targeting three classical signaling pathways, as well as dual-, sequential triple-, and initial triple-therapy strategies based on the aforementioned targeted agents. More crucially, the search for novel therapeutic targets for PAH has never stopped, with great progress in recent years, and this review outlines the potential PAH therapeutic agents currently in the exploratory stage to provide new directions for the treatment of PAH and improve the long-term prognosis of PAH patients.

Management of PH-ILD: Past, Present, and Future

Evolution of pulmonary hypertension in interstitial lung disease: a journey through past, present, and future

Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension

Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?

Use of inhaled treprostinil in patients with interstitial lung disease and pulmonary hypertension: to boldly go where no other pulmonary vasodilator has gone before?

Pulmonary hypertension in interstitial lung disease: an area of unmet clinical need

PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis

Pulmonary Hypertension in Interstitial Lung Disease: A Systematic Review and Meta-Analysis

A Case of Interstitial Lung Disease-Related Pulmonary Hypertension Successfully Treated with Inhaled Iloprost

Mechanisms and treatment of pulmonary arterial hypertension

Inhaled Treprostinil in Pulmonary Hypertension Associated with Lung Disease

Efficacy and Determinants of Response to Inhaled Treprostinil in Pulmonary Hypertension - Interstitial Lung Disease

Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension

Inhaled pulmonary vasodilators: a narrative review

Management of patients with fibrosing interstitial lung diseases

Pharmacological Treatment of Interstitial Lung Diseases: A Novel Landscape for Inhaled Agents

Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease

Intravenous prostacyclin-analogue therapy in pulmonary arterial hypertension - A review of the past, present and future

Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review

Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs

Pharmacotherapy of refractory pulmonary arterial hypertension